Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation

Autor(es)

dos Santos, Sofia Nascimento ; Sheldon, Helen ; Pereira, Jonathas Xavier ; Paluch, Christopher ; Bridges, Esther M. ; El-Cheikh, Marcia Curry ; Harris, Adrian L. ; Bernardes, Emerson Soares

• Tipo de documento: Artigo Científico
• Fonte: ONCOTARGET; v. 8, n. 30, p. 49484-49501, JUL 25 2017.
• Citações Web of Science: 16

Resumo

Angiogenesis is a coordinated process tightly regulated by the balance between Delta-like-4 (DLL4) and Jagged-1 (JAG1) in endothelial cells. Here we show that galectin-3 (gal-3), a glycan-binding protein secreted by cancer cells under hypoxic conditions, triggers sprouting angiogenesis, assisted by hypoxic changes in the glycosylation status of endothelial cells that enhance binding to gal-3. Galectin-3' s proangiogenic functions were found to be predominantly dependent on the Notch ligand JAG1. Differential direct binding to JAG1 was shown by surface plasmon resonance assay. Upon binding to Notch ligands, gal-3 preferentially increased JAG1 protein half-life over DLL4 and preferentially activated JAG1/Notch-1 signaling in endothelial cells. JAG1 overexpression in Lewis lung carcinoma cells accelerated tumor growth in vivo, but this effect was prevented in Lgals3(-/-) mice. Our findings establish gal-3 as a molecular regulator of the JAG1/Notch-1 signaling pathway and have direct implications for the development of strategies aimed at controlling tumor angiogenesis. (AU)

• Processo FAPESP: 12/06875-6 - Desenvolvimento e produção de radiofármacos emissores de pósitrons com aplicações diagnósticas em oncologia
• Beneficiário: Emerson Soares Bernardes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores